DAIS ANALYTIC CORP Form 8-K February 05, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 30, 2015

DAIS ANALYTIC CORPORATION

(Exact name of registrant as specified in its charter)

New York 000-53554 14-760865
(State or other jurisdiction of (Commission File No.) (IRS Employer incorporation or organization)

11552 Prosperous Drive

Odessa, Florida 33556

(Address of Principal Executive Offices)(Zip Code)

(727) 375-8484

(Registrant's telephone number, including area code)

Edgar Filing: DAIS ANALYTIC CORP - Form 8-K

<u>N/A</u>

(Former name or former address, if changed since last report)

Copies to:

Peter DiChiara, Esq.

SICHENZIA ROSS FRIEDMAN FERENCE LLP

61 Broadway, 32nd Floor

New York, New York 10006

Telephone: (212) 930-9700

Facsimile: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- "Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.02 Unregistered Sales of Equity Securities.

As reported in a Current Report on Form 8-K filed on December 19, 2014 by Dais Analytic Corporation (the "Company"), the Company entered into a Securities Purchase Agreement (the "SPA") with two investors pursuant to which the Company agreed to sell 18,000,000 shares of the Company's common stock, \$0.01 par value per share (the "Common Stock"), for \$2,750,000, at approximately \$0.153 per share pursuant to Regulation S. The Company received consideration of \$2,750,000 from the investors and issued the 18,000,000 shares of Common Stock to the investors. The Company shall use the proceeds from the sale of the Common Stock for working capital and business development.

2

Edgar Filing: DAIS ANALYTIC CORP - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dais Analytic Corporation

Dated: February 5, 2015 By: /s/ Timothy N. Tangredi

Timothy N. Tangredi

Chief Executive Officer and

President

3